Zydus Lifesciences Reaches $120 Million Patent Settlement with Astellas Over Mirabegron in US Market
The agreement resolves ongoing patent litigation, enabling Zydus to market its generic Mirabegron while compensating Astellas through upfront and royalty payments until 2027
Zydus Lifesciences and its US subsidiary have finalized a patent dispute settlement with Astellas Pharma concerning the US rights to Mirabegron, marketed as Myrbetriq by Astellas. Under the terms, Zydus will pay $120 million upfront plus a per-unit royalty on generic sales through September 2027, allowing uninterrupte…
